The power and pitfalls of IL-12

Blood

Volumn 119, Issue 18, 2012, Pages 4096-4097

  Kerkar, Sid P ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG MEGADOSE; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; MELANOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR MODEL;

EID: 84860766928     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-415018     Document Type: Note

References (10)

1. Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targetedTcells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 119(18):4133-4141.
2. Kerkar SP, Goldszmid RS, Muranski P, et al. IL-12 triggers a programmatic change in dysfunctional myeloidderived cells within mouse tumors. J Clin Invest. 2011; 121(12):4746-4757.
3. Kerkar SP, Muranski P, Kaiser A, et al. Tumor-specific CD8 Tcells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010;70(17):6725-6734.
4. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541-2548. (Pubitemid 27413462)
5. Chinnasamy D, Yu Z, Kerkar SP, et al. Local delivery of interleukin-12 usingTcells targeting vascular endothelial growth factor receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res. 2012;18:1672.
6. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineeredTcells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17): 5697-5706.
7. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologousTcells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
8. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targetedTcells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
9. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy.NEngl J Med. 2011;365(18):1673-1683.
10. Zhang L, Kerkar SP, Yu Z, et al. Improving adoptiveT cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011;19(4):751-759.